Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses

Journal of Pediatric Hematology/Oncology

Volumn 24, Issue 6, 2002, Pages 447-453

  Bharatan, Neeti S ^a   Currier, Mark A ^a   Cripe, Timothy P ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Ewing sarcoma; Herpes simplex virus; Oncolysis; Osteosarcoma; Rhabdomyosarcoma

Indexed keywords

BETA GALACTOSIDASE; RIBONUCLEOTIDE REDUCTASE; VIRUS VECTOR;

ARTICLE; CANCER CELL CULTURE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; EWING SARCOMA; GENE DELETION; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MALIGNANT FIBROUS HISTIOCYTOMA; OSTEOSARCOMA; PRIORITY JOURNAL; REPORTER GENE; RHABDOMYOSARCOMA; SARCOMA CELL; VIRUS ATTENUATION; VIRUS REPLICATION;

BETA-GALACTOSIDASE; CELL SURVIVAL; CHILD; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; OSTEOSARCOMA; RHABDOMYOSARCOMA; SARCOMA, EWING'S; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0036694323     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200208000-00008     Document Type: Article

References (37)

1. Meyers P, Krailo M, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001;19:2812-20.
2. Weigel B, Breitfeld P, Hawkins D, et al. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J Pediatr Hematol Oncol 2001;23:272-6.
3. Mackall C, Helman L. High-dose chemotherapy for rhabdomyosarcoma: where do we go from here? J Pediatr Hematol Oncol 2001;23:266-7.
4. Kenney S, Pagano J. Viruses as oncolytic agents: a new age for "therapeutic" viruses? J Nat Cancer Inst 1994;86:1185-6.
5. Coffey MC, Strong JE, Forsyth PA, et al. Reovirus therapy of tumors with activated Ras pathway. Science 1998;282:1332-4.
6. Heise C, Kim D. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000;105:847-51.
7. Martuza R. Conditionally replicating herpes vectors for cancer therapy. J Clin Invest 2000;105:841-6.
8. Meignier B, Longnecker R, Roizman B. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents. J Infect Dis 1988;158:602-14.
9. Sundaresan P, Hunter WD, Martuza RL, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation in mice. J Virol 2000;74:3832-41.
10. Meignier B, Martin B, Whitley R, et al. In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020. II. Studies in immunocompetent and immunosuppressed owl monkeys (aotus trivirgatus). J Infect Dis 1990;162:313-21.
11. Hunter WD, Martuza RL, Feigenbaum F, et al. Attenuated, replication-competent herpes simplex virus type 1 mutant G207: safety evaluation of intracerebral injection in nonhuman primates. J Virol 1999;73:6319-26.
12. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74.
13. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859-66.
14. Roizman B, Sears A. Herpes simplex viruses and their replication. In: Knipe DM, Fields BN, Howley PM, eds. Fields virology, Ed. 5. Philadelphia: Lippincott-Raven; 1996:2231-95.
15. Pawlik TM, Nakamura H, Yoon SS, et al. Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus. Cancer Res 2000;60:2790-5.
16. Toda M, Rabkin SD, Martuza RL. Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum Gene Ther 1998;9:2177-85.
17. Carew JF, Kooby DA, Halterman MW, et al. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum Gene Ther 1999;10:1599-606.
18. Kasuya H, Nishiyama Y, Nomoto S, et al. Intraperitoneal delivery of hrR3 and ganciclovir prolongs survival in mice with disseminated pancreatic cancer. J Surg Oncol 1999;72:136-41.
19. Walker JR, McGeagh KG, Sundaresan P, et al. Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum Gene Ther 1999;10:2237-43.
20. Coukos G, Makrigiannakis A, Montas S, et al. Multi-attenuated herpes simplex virus-1 mutant G207 exerts cytotoxicity against epithelial ovarian cancer but not normal mesothelium and is suitable for intraperitoneal oncolytic therapy. Cancer Gene Ther 2000;7:275-83.
21. Oyama M, Ohigashi T, Hoshi M, et al. Intravesical and intravenous therapy of human bladder cancer by the herpes vector G207. Hum Gene Ther 2000;11:1683-93.
22. Nicolo M, Chiocca EA. Marker gene transfer and oncolysis of human Y79 retinoblastoma cells mediated by herpes simplex virus mutants. Ophthalmic Res 1998;30:30-6.
23. Toda M, Rabkin SD, Kojima H, et al. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999;10:385-93.
24. Todo T, Rabkin SD, Sundaresan P, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999;10:2741-55.
25. Chen Y, Chen P, Arnaiz N, et al. Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate. Oncogene 1991;6:1799-1805.
26. Sorensen P, Liu X, Delattre O, et al. Reverse transcriptase PCR amplification of EWS/FLI-1 fusion transcripts as a diagnostic test for peripheral primitive neuroectodermal tumors of childhood. Diagnostic Mol Pathol 1993;2:147-57.
27. Toretsky JA, Connell Y, Neckers L, et al. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 1997;31:9-16.
28. Cripe T, Dunphy E, Holub A, et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor which limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res 2001;61:2953-60.
29. Mineta T, Rabkin SD, Yazaki T, et al. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1995;1:938-43.
30. Li Y, Pong R, Bergelson J, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res 1999;59:325-30.
31. Okegawa T, Li Y, Pong R-C, et al. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy. Cancer Res 2000;60:5031-6.
32. Vanderkwaak T, Wang M, Gomez-Navarro J, et al. An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gyn Oncol 1999;74:227-34.
33. Yamamura H, Hashio M, Noguchi M, et al. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res 2001;61:3969-77.
34. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001;8:89-98.
35. Netti P, Berk D, Swartz M, et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497-2503.
36. Chen Y, De-Chao Y, Charlton D, et al. Pre-existent adenovirus antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse LNCaP xenograft model: implications and proposals for human therapy. Hum Gene Ther 2000;11:1553-67.
37. Delman KA, Bennett JJ, Zager JS, et al. Effects of preexisting immunity on the response to herpes simplex-based oncolytic viral therapy. Hum Gene Ther 2000;11:2465-72.